Investigating how chromatin remodelers affect immune cells in cancer
SWI/SNF chromatin remodelers in tumor-associated antigen-specific CD8+ cytotoxic T cells
This study is looking at how changes in a protein called FOXA1 affect immune cells that fight cancer in men with prostate cancer, hoping to find new ways to improve treatments and help patients live better lives.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-10915002 on NIH RePORTER |
What this research studies
This research focuses on understanding how specific changes in a transcription factor called FOXA1 influence the behavior of immune cells, particularly CD8+ cytotoxic T cells, in hormone-driven cancers like prostate cancer. By analyzing a large cohort of prostate cancer samples, the study aims to identify distinct alterations in FOXA1 that may affect cancer progression and immune response. The researchers will use innovative chromatin-based techniques to explore how these changes can be targeted for therapeutic purposes, potentially improving treatment outcomes for patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with hormone-receptor driven prostate cancer, particularly those with metastatic disease.
Not a fit: Patients with non-hormone receptor driven cancers or those without prostate cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies that enhance the immune response against prostate cancer.
How similar studies have performed: Previous research has shown promising results in targeting chromatin remodelers in cancer, suggesting that this approach may lead to significant advancements in treatment.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Parolia, Abhijit — University of Michigan at Ann Arbor
- Study coordinator: Parolia, Abhijit
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.